Everstone Capital buys controlling stake in Calibre Chemicals for Rs 730 crore
Advertisement
Mumbai: Singapore-headquartered private equity major Everstone Capital on Tuesday announced acquisition of a controlling stake in Calibre Chemicals, which is a specialty ingredients player focused on the pharmaceutical, nutritional and personal care segments, for a reported USD 100 million (around Rs 730 crore).
The city-based, privately-held Calibre was established in 1984 and manufactures a range of specialty chemicals falling into two product lines--mineral derivatives (iodine, selenium, cobalt) and peroxygens (persulphates, perchlorates).
Read also: Pfizer to buy Trillium Therapeutics in USD 2.26 billion deal
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.